Physician profile
Pio Clavecilla
NPI 1659349140
$871.51
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $102 · 2021: $68.63 · 2022: $41.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $220.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.70 | 2019-2020 | |
| Pfizer INC. | $133.17 | 2019-2020 | |
| Genzyme Corporation | $90.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.87 | 2019-2022 | |
| Amgen INC. | $46.33 | 2019 | |
| Merck Sharp & Dohme LLC | $43.18 | 2020-2021 | |
| Lifescan, INC. | $24.36 | 2022 | |
| Daiichi Sankyo INC. | $23.45 | 2021 | |
| Glaxosmithkline, LLC. | $17.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.29 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.04 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pio Clavecilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.